Academic Journal
Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease
| العنوان: | Lenalidomide as a novel therapy for gastrointestinal angiodysplasia in von Willebrand disease |
|---|---|
| المؤلفون: | Khatri, N. V., Patel, B., Kohli, D. R., Solomon, S. S., Bull‐Henry, K., Kessler, C. M. |
| المصدر: | Haemophilia ; volume 24, issue 2, page 278-282 ; ISSN 1351-8216 1365-2516 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2018 |
| المجموعة: | Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: | Introduction Lenalidomide is a thalidomide analog with anti‐angiogenic properties. Previous case reports suggest its efficacy in preventing gastrointestinal bleeding ( GIB ) secondary to angiodysplasia ( AD ) in hereditary haemorrhagic telangiectasia and potentially in reversing AD . We present the first case series to explore lenalidomide as a treatment for AD ‐related GIB in patients with von Willebrand disease ( VWD ). Methods A retrospective chart review was conducted to include patients with VWD , who were evaluated from 2010 to 2013 and who had received lenalidomide to treat recurrent GIB secondary to AD . All patients had failed single‐agent use of antifibrinolytic agents. Patients were observed for at least 2 years on therapy. Results Five patients (3 males; 68.2 ± 4.9 years) with VWD (3 with type 3 and 1 each with types 1 and 2a) and AD were found. Sites of AD included the stomach, duodenum, jejunum and colon. Lenalidomide was started at 5 mg oral daily. Uptitration to 10 and 15 mg in 1 patient each was necessary due to recurrence of GIB . The mean number of endoscopies performed for control of GIB post lenalidomide was significantly lower compared to pretherapy (0.25 vs 5.50; P = .001). Mean bleed‐free duration on lenalidomide was 12.6 ± 4.7 months. Three patients have reported no GIB on lenalidomide. Conclusion This case series demonstrates significantly reduced number of endoscopies and increased bleed‐free duration with lenalidomide treatment in selected patients with VWD and recurrent GIB from AD . Prospective multicenter trials are needed to further define the role of lenalidomide in the management of GIB from angiodysplasia and VWD . |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1111/hae.13419 |
| الاتاحة: | http://dx.doi.org/10.1111/hae.13419 https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fhae.13419 https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13419 |
| Rights: | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| رقم الانضمام: | edsbas.67A1DE7C |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/hae.13419 |
|---|